300142 On Other Exchanges
300142 is not on other exchanges.

walvax biotechnology co-a (300142) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WALVAX BIOTECHNOLOGY CO-A (300142)

Related News

No related news articles were found.

walvax biotechnology co-a (300142) Related Businessweek News

No Related Businessweek News Found

walvax biotechnology co-a (300142) Details

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, engages in the research and development, production, and sale of bio-medicine products in China. It offers bio-medicines, such as vaccines, blood products, and others. The company provides Group A and C meningococcal polysaccharide vaccine for children over the age of 2 years and adults to prevent disease caused by the bacteria named Neisseria meningitidis groups A and group C; Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. It also offers haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, the company provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine. Further, it offers 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.

Founded in 2001

walvax biotechnology co-a (300142) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

walvax biotechnology co-a
Walvax Biotechnology Plans To Sell Shanghai-Based Pharma-Tech Unit

Walvax Biotechnology Co., Ltd. (SZSE:300142) is planning to sell Shanghai-based pharma-tech unit for CNY 10 million.

Walvax Biotechnology Co., Ltd. Announces Board Appointments

Walvax Biotechnology Co., Ltd. at its extraordinary general meeting held on December 28, 2017, elected Xu Wansheng, Kang Jun, and Wu Yu as non-independent directors.

Walvax Biotechnology Co., Ltd., Board Meeting, Dec 28, 2017

Walvax Biotechnology Co., Ltd., Board Meeting, Dec 28, 2017, at 14:00 China Standard Time. Agenda: To approve the election of non-independent directors; and to approve election of Wei Aixue as a non-employee supervisor.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

300142 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300142.
View Industry Companies

Industry Analysis


Industry Average

Valuation 300142 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 47.7x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact WALVAX BIOTECHNOLOGY CO-A, please visit www.walvax.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.